Skip to main content

Table 3 Odds ratios (95% confidence interval) of developing subsequent breast cancer according to cross-classified groups of EZH2 and ER, and Ki67 in normal breast tissue

From: EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses’ Health Studies

 

Cases

Controls

Model 1a

OR (95% CI)

Model 2b

OR (95% CI)

Low EZH2/low ER

10

38

1.0 (Ref)

1.0 (Ref.)

Low EZH2/high ER

7

35

0.97 (0.32–2.94)

1.07 (0.35–3.31)

High EZH2/low ER

12

15

3.90 (1.27–11.99)

4.02 (1.29–12.59)

High EZH2/high ER

1

18

0.24 (0.03–2.09)

0.19 (0.02–1.70)

P value for interaction

  

0.031

0.017

Low EZH2/low Ki67

13

65

1.0 (Ref.)

1.0 (Ref.)

Low EZH2/high Ki67

7

29

1.49 (0.51–4.34)

1.56 (0.53–4.59)

High EZH2/low Ki67

12

31

2.62 (0.98–7.01)

2.40 (0.88–6.51)

High EZH2/high Ki67

22

68

1.67 (0.73–3.83)

1.78 (0.77–4.14)

P value for interaction

  

0.235

0.306

  1. Matching factors: age at cancer diagnosis/index date, year of biopsy and, time between benign breast disease (BBD) biopsy and cancer diagnosis/index date. Enhancer of zeste homolog 2 (EZH2), estrogen receptor (ER) and Ki67 expression categorized by median expression percentage. Only EZH2 epithelial expression was considered for cross-classification. aModel 1: adjusting for matching factors, bModel 2: adjusting for matching factors and BBD category. Ref. reference